NCT01357993View on ClinicalTrials.gov

A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Attention-Deficit / Hyperactivity Disorder
Interventions
DRUG

JNS001

18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks

Trial Locations (29)

Unknown

Chiba

Chigasaki

Chiyoda City

Fuchū

Fukuoka

Fukushima

Hamamatsu

Higashiosaka

Ichikawa

Iruma

Isehara

Kashihara

Kishiwada

Kobe

Kumamoto

Kurume

Matsuyama

Nagasaki

Nagoya

Nara

Neyagawa

Osaka

Saitama

Sakai

Sapporo

Shibuya City

Takatsuki

Tokyo

Yokohama

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT01357993 - A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder | Biotech Hunter | Biotech Hunter